Terns Pharmaceuticals Inc (NASDAQ: TERN) is 54.39% higher on its value in year-to-date trading and has touched a low of $3.26 and a high of $11.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TERN stock was last observed hovering at around $10.04 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $10.02, the stock is 15.22% and 21.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.96 million and changing -0.20% at the moment leaves the stock 46.68% off its SMA200. TERN registered 95.70% gain for a year compared to 6-month gain of 52.98%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 27.16% loss in the last 1 month and extending the period to 3 months gives it a 38.59%, and is 11.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.64% over the week and 9.50% over the month.
Terns Pharmaceuticals Inc (TERN) has around 66 employees, a market worth around $846.09M and $0.00M in sales. Distance from 52-week low is 207.36% and -12.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-43.85%).
The EPS is expected to shrink by -1.07% this year.
Terns Pharmaceuticals Inc (TERN) Top Institutional Holders
175.0 institutions hold shares in Terns Pharmaceuticals Inc (TERN), with institutional investors hold 85.40% of the company’s shares. The shares outstanding are 64.58M, and float is at 59.14M with Short Float at 4.49%. Institutions hold 84.33% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 7.62 million shares valued at $51.89 million. The investor’s holdings represent 10.2326% of the TERN Shares outstanding. As of 2024-06-30, the second largest holder is VIVO CAPITAL, LLC with 6.18 million shares valued at $42.11 million to account for 8.3038 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 6.1 million shares representing 8.1923% and valued at over $41.54 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 6.6448 of the shares totaling 4.95 million with a market value of $33.69 million.
Terns Pharmaceuticals Inc (TERN) Insider Activity
The most recent transaction is an insider purchase by Lu Hongbo, the company’s Director. SEC filings show that Lu Hongbo bought 476,190 shares of the company’s common stock on Sep 12 ’24 at a price of $10.50 per share for a total of $5.0 million. Following the purchase, the insider now owns 0.48 million shares.
Terns Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 10 ’24 that Vignola Mark J. (Chief Financial Officer) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Sep 10 ’24 and was made at $11.00 per share for $0.11 million. Following the transaction, the insider now directly holds 91940.0 shares of the TERN stock.
Still, SEC filings show that on Sep 09 ’24, Quigley Jill M. (Director) disposed off 17,235 shares at an average price of $10.00 for $0.17 million. The insider now directly holds 15,000 shares of Terns Pharmaceuticals Inc (TERN).
